This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Patel, V. Articles by Senderowicz, A. M. Search for Related Content PubMed PubMed Citation Articles by Patel, V. Articles by Senderowicz, A. M.

Perifosine, a Novel Alkylphospholipid, Induces p21^WAF1 Expression in Squamous Carcinoma Cells through a p53-independent Pathway, Leading to Loss in Cyclin-dependent Kinase Activity and Cell Cycle Arrest

Oral and Pharyngeal Cancer Branch, National Institute of Craniofacial and Dental Research [V. P., T. L., T. S., J. S. G., A. M. S.], and Developmental Therapeutics Program, Division of Cancer Treatment and Diagnosis, National Cancer Institute [E. A. S.], NIH, Bethesda, Maryland 20892

Alkylphospholipids (ALKs) are a novel class of antineoplastic compounds that display potent antiproliferative activity against several in vitro and in vivo human tumor models. However, the mechanism by which these agents exert this desired effect is still unclear. In this study, we investigated the effect of perifosine, a p.o.-bioavailable ALK, on the cell cycle kinetics of immortalized keratinocytes (HaCaT) as well as head and neck squamous carcinoma cells. All cells were sensitive to the antiproliferative properties of perifosine with an IC₅₀ of 0.6–8.9 µM. Cell cycle arrest at the G₁-S and G₂-M boundaries was observed in HN12, HN30, and HaCaT cells independent of p53 function, and this effect was preceded by loss in cdc2 and cyclin-dependent kinase (cdk) 2 activity. Analysis of cdk complexes in vitro demonstrated that perifosine, up to 20 µM, did not directly interfere with these enzymes. However, aphidicolin-synchronized HN12 cells released in the presence of perifosine (10 µM) demonstrated increased expression of total p21^WAF1 and increased association of p21^WAF1 with cyclin-cdk complexes resulting in reduced cdc2 activity. HCT116 isogenic cell lines were used to assess the role of p21^WAF1 induction by perifosine. This compound (20 µM) induced both G₁-S and G₂-M cell cycle arrest, together with p21^WAF1 expression in both p53 wild-type and p53^-/- clones. By contrast, p21^-/- variants demonstrated no p21^WAF1 induction or cell cycle arrest. Similar results were obtained with other ALK congeners (miltefosine and edelfosine). These data, therefore, indicate that perifosine blocks cell cycle progression of head and neck squamous carcinoma cells at G₁-S and G₂-M by inducing p21^WAF1, irrespective of p53 function, and may be exploited clinically because the majority of human malignancies harbor p53 mutations.

This article has been cited by other articles:

				X. Leleu, J. Eeckhoute, X. Jia, A. M. Roccaro, A.-S. Moreau, M. Farag, A. Sacco, H. T. Ngo, J. Runnels, M. R. Melhem, et al. Targeting NF-{kappa}B in Waldenstrom macroglobulinemia Blood, May 15, 2008; 111(10): 5068 - 5077. [Abstract] [Full Text] [PDF]

				R. L. Vinall, K. Hwa, P. Ghosh, C.-X. Pan, P. N. Lara Jr., and R. W. de Vere White Combination Treatment of Prostate Cancer Cell Lines with Bioactive Soy Isoflavones and Perifosine Causes Increased Growth Arrest and/or Apoptosis Clin. Cancer Res., October 15, 2007; 13(20): 6204 - 6216. [Abstract] [Full Text] [PDF]

				H. A. Elrod, Y.-D. Lin, P. Yue, X. Wang, S. Lonial, F. R. Khuri, and S.-Y. Sun The alkylphospholipid perifosine induces apoptosis of human lung cancer cells requiring inhibition of Akt and activation of the extrinsic apoptotic pathway Mol. Cancer Ther., July 1, 2007; 6(7): 2029 - 2038. [Abstract] [Full Text] [PDF]

				T. Hideshima, L. Catley, H. Yasui, K. Ishitsuka, N. Raje, C. Mitsiades, K. Podar, N. C. Munshi, D. Chauhan, P. G. Richardson, et al. Perifosine, an oral bioactive novel alkylphospholipid, inhibits Akt and induces in vitro and in vivo cytotoxicity in human multiple myeloma cells Blood, May 15, 2006; 107(10): 4053 - 4062. [Abstract] [Full Text] [PDF]

				S. R. Vink, S. Lagerwerf, E. Mesman, J. H.M. Schellens, A. C. Begg, W. J. van Blitterswijk, and M. Verheij Radiosensitization of Squamous Cell Carcinoma by the Alkylphospholipid Perifosine in Cell Culture and Xenografts Clin. Cancer Res., March 1, 2006; 12(5): 1615 - 1622. [Abstract] [Full Text] [PDF]

				H. Momota, E. Nerio, and E. C. Holland Perifosine Inhibits Multiple Signaling Pathways in Glial Progenitors and Cooperates With Temozolomide to Arrest Cell Proliferation in Gliomas In vivo Cancer Res., August 15, 2005; 65(16): 7429 - 7435. [Abstract] [Full Text] [PDF]

				M. F. Aguero, M. M. Facchinetti, Z. Sheleg, and A. M. Senderowicz Phenoxodiol, a Novel Isoflavone, Induces G1 Arrest by Specific Loss in Cyclin-Dependent Kinase 2 Activity by p53-Independent Induction of p21WAF1/CIP1 Cancer Res., April 15, 2005; 65(8): 3364 - 3373. [Abstract] [Full Text] [PDF]

				M. Rahmani, E. Reese, Y. Dai, C. Bauer, S. G. Payne, P. Dent, S. Spiegel, and S. Grant Coadministration of Histone Deacetylase Inhibitors and Perifosine Synergistically Induces Apoptosis in Human Leukemia Cells through Akt and ERK1/2 Inactivation and the Generation of Ceramide and Reactive Oxygen Species Cancer Res., March 15, 2005; 65(6): 2422 - 2432. [Abstract] [Full Text] [PDF]

				L. Van Ummersen, K. Binger, J. Volkman, R. Marnocha, K. Tutsch, J. Kolesar, R. Arzoomanian, D. Alberti, and G. Wilding A Phase I Trial of Perifosine (NSC 639966) on a Loading Dose/Maintenance Dose Schedule in Patients with Advanced Cancer Clin. Cancer Res., November 15, 2004; 10(22): 7450 - 7456. [Abstract] [Full Text] [PDF]

				G. P. Dasmahapatra, P. Didolkar, M. C. Alley, S. Ghosh, E. A. Sausville, and K. K. Roy In vitro Combination Treatment with Perifosine and UCN-01 Demonstrates Synergism against Prostate (PC-3) and Lung (A549) Epithelial Adenocarcinoma Cell Lines Clin. Cancer Res., August 1, 2004; 10(15): 5242 - 5252. [Abstract] [Full Text] [PDF]

				M. M. Facchinetti, A. De Siervi, D. Toskos, and A. M. Senderowicz UCN-01-Induced Cell Cycle Arrest Requires the Transcriptional Induction of p21waf1/cip1 by Activation of Mitogen-Activated Protein/Extracellular Signal-Regulated Kinase Kinase/Extracellular Signal-Regulated Kinase Pathway Cancer Res., May 15, 2004; 64(10): 3629 - 3637. [Abstract] [Full Text] [PDF]

				A. De Siervi, M. Marinissen, J. Diggs, X.-F. Wang, G. Pages, and A. Senderowicz Transcriptional Activation of p21waf1/cip1 by Alkylphospholipids: Role of the Mitogen-Activated Protein Kinase Pathway in the Transactivation of the Human p21waf1/cip1 Promoter by Sp1 Cancer Res., January 15, 2004; 64(2): 743 - 750. [Abstract] [Full Text] [PDF]

				S. Fukuda, C. R. Mantel, and L. M. Pelus Survivin regulates hematopoietic progenitor cell proliferation through p21WAF1/Cip1-dependent and -independent pathways Blood, January 1, 2004; 103(1): 120 - 127. [Abstract] [Full Text] [PDF]

				S. B. Kondapaka, S. S. Singh, G. P. Dasmahapatra, E. A. Sausville, and K. K. Roy Perifosine, a novel alkylphospholipid, inhibits protein kinase B activation Mol. Cancer Ther., November 1, 2003; 2(11): 1093 - 1103. [Abstract] [Full Text] [PDF]

				H. Lapillonne, M. Konopleva, T. Tsao, D. Gold, T. McQueen, R. L. Sutherland, T. Madden, and M. Andreeff Activation of Peroxisome Proliferator-activated Receptor {gamma} by a Novel Synthetic Triterpenoid 2-Cyano-3,12-dioxooleana-1,9-dien-28-oic Acid Induces Growth Arrest and Apoptosis in Breast Cancer Cells Cancer Res., September 15, 2003; 63(18): 5926 - 5939. [Abstract] [Full Text] [PDF]

				M. Frederich, M. Bentires-Alj, M. Tits, L. Angenot, R. Greimers, J. Gielen, V. Bours, and M.-P. Merville Isostrychnopentamine, an Indolomonoterpenic Alkaloid from Strychnos usambarensis, Induces Cell Cycle Arrest and Apoptosis in Human Colon Cancer Cells J. Pharmacol. Exp. Ther., March 1, 2003; 304(3): 1103 - 1110. [Abstract] [Full Text] [PDF]